tiprankstipranks
Advertisement
Advertisement
Luye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive Dyskinesia
PremiumCompany AnnouncementsLuye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive Dyskinesia
3M ago
Luye Pharma Halves 2028 Convertible Bond Float With US$89.74 Million Buyback
Premium
Company Announcements
Luye Pharma Halves 2028 Convertible Bond Float With US$89.74 Million Buyback
3M ago
Luye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds
Premium
Company Announcements
Luye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds
3M ago
Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015
PremiumCompany AnnouncementsLuye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015
5M ago
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
Premium
Company Announcements
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
5M ago
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
Premium
Company Announcements
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
5M ago
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
PremiumCompany AnnouncementsLuye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
8M ago
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
Premium
Company Announcements
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
8M ago
Luye Pharma Outlines Board Line-Up and Committee Structure
Premium
Company Announcements
Luye Pharma Outlines Board Line-Up and Committee Structure
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100